Literature DB >> 25125379

Diagnostic and clinical characteristics of early-manifesting females with Duchenne or Becker muscular dystrophy.

Lauren Imbornoni1, Elinora T Price, Jennifer Andrews, F John Meaney, Emma Ciafaloni, Christopher Cunniff.   

Abstract

Manifestations of Duchenne and Becker muscular dystrophy (DBMD) are present in up to 40% of heterozygous females, but there are few reports of females who exhibit skeletal muscle symptoms in childhood. From the Muscular Dystrophy Surveillance Tracking and Research Network, a multi-site population-based surveillance network for dystrophinopathy, nine symptomatic female heterozygotes with onset of symptoms prior to age 9 years were identified. The median age at diagnosis was 8.3 years, and the median interval from first symptoms to diagnosis was 1.35 years. Of the nine female heterozygotes, four had a positive family history, seven had intellectual disability and five had at least one mental health disorder. Mental health concerns included attention deficit hyperactivity disorder (ADHD), autism spectrum features, bipolar disorder, and depression. The frequency of intellectual and mental health problems in this group is higher than previously reported for affected males and for symptomatic females. These findings may have implications for diagnosis of early manifesting heterozygotes and for their health supervision.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  duchenne muscular dystrophy; dystrophinopathy; manifesting heterozygote

Mesh:

Substances:

Year:  2014        PMID: 25125379     DOI: 10.1002/ajmg.a.36728

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

Review 1.  A Review of MD STAR net's Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 2002-2017.

Authors:  Kashika M Sahay; Tiffany Smith; Kristin M Conway; Paul A Romitti; Molly M Lamb; Jennifer Andrews; Shree Pandya; Joyce Oleszek; Christopher Cunniff; Rodolfo Valdez
Journal:  J Child Neurol       Date:  2018-10-22       Impact factor: 1.987

2.  Medical Attitudes Survey for Female Dystrophinopathy Carriers in Japan.

Authors:  Michio Kobayashi; Tomoyuki Hatakeyama; Masatoshi Ishizaki; Katsuhito Adachi; Mizuki Morita; Naohiro Yonemoto; Tsuyoshi Matsumura; Itaru Toyoshima; En Kimura
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

3.  First psychotic episode in an adult with Becker muscular dystrophy.

Authors:  Cátia Fernandes Santos
Journal:  Braz J Psychiatry       Date:  2019-06-10       Impact factor: 2.697

4.  In vivo cerebellar circuit function is disrupted in an mdx mouse model of Duchenne muscular dystrophy.

Authors:  Trace L Stay; Lauren N Miterko; Marife Arancillo; Tao Lin; Roy V Sillitoe
Journal:  Dis Model Mech       Date:  2019-12-09       Impact factor: 5.758

5.  Serum Levels of MicroRNA-206 and Novel Mini-STR Assays for Carrier Detection in Duchenne Muscular Dystrophy.

Authors:  Mónica Alejandra Anaya-Segura; Héctor Rangel-Villalobos; Gabriela Martínez-Cortés; Benjamín Gómez-Díaz; Ramón Mauricio Coral-Vázquez; Edgar Oswaldo Zamora-González; Silvia García; Luz Berenice López-Hernández
Journal:  Int J Mol Sci       Date:  2016-08-13       Impact factor: 5.923

6.  Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up.

Authors:  Amir Dori; Michela Guglieri; Marianna Scutifero; Luigia Passamano; Antonio Trabacca; Luisa Politano
Journal:  Acta Myol       Date:  2021-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.